Bayer Balances Missouri Jury Win Against $7.25 Billion Settlement Review as Brokers Split on Targets
Published on 11/09/2026 at 07:31 | Editorial boerse-global.de
Bayer's legal calendar and its pharmaceutical pipeline are pulling the stock in opposite directions, and the brokerage community is responding with targets that point in much the same divergent fashion. Monsanto, the company's subsidiary, secured a unanimous jury verdict in its favour on 29 October in a Roundup case in Missouri, resolving claims brought by three women. That win does not touch the separate settlement proposal still sitting before a Missouri court.
The proposed deal carries a price tag of 7.25 billion US dollars. CEO Bill Anderson said roughly a week ago that Bayer expects a decision before Christmas, though the company framed this as its own expectation rather than a confirmed date from the bench.
Targets move higher, recommendations stay apart
Jefferies lifted its price target on Bayer to 48.50 euros from 46 following the quarterly figures, keeping its rating at "Hold" — a higher number without a buy signal attached. UBS moved on 3 November, raising its target to 66 euros from 62 and reaffirming "Buy," citing momentum in the pharmaceuticals business and the planned break-up of rival Corteva. J.P. Morgan also weighed in that same day, restating "Overweight" with a 61-euro target.
The gap between Hold and Buy is wide, and the shares reflected little of the enthusiasm: Bayer slipped 0.7% on Friday after the two analyst moves.
Should investors sell immediately? Or is it worth buying Bayer?
Guidance raised on pharma strength
A week earlier, Bayer reported third-quarter 2026 group revenue of 10.1 billion euros and EBITDA before special items of 1.62 billion euros. The pharmaceuticals division contributed 4.68 billion euros in sales, up 6.4% on a currency- and portfolio-adjusted basis. Reuters tied the accompanying guidance upgrade to the strength of the drug business.
The group now expects EBITDA before special items of 9.8 to 10.3 billion euros for the year, up from a prior range of 9.6 to 10.1 billion euros. Free cash flow guidance was lifted to between minus 1.5 and minus 0.5 billion euros. Net financial debt at year-end is projected at 28 to 29 billion euros.
Litigation remains a heavy cash drain. Reuters reported that Bayer anticipated roughly 5 billion euros of outflows in 2026 for settlements, judgments and legal fees.
Bayer at a turning point? This analysis reveals what investors need to know now.
China clears Sevabertinib; heart data queued for Chicago
On the regulatory front, China granted Sevabertinib approval as a first-line treatment for adults with advanced HER2-mutated non-small cell lung cancer, based on results from the ongoing Phase I/II SOHO-01 trial. Bayer also said it will present new data on cardiovascular disease, kidney disease and stroke at the AHA Scientific Sessions, scheduled for 6 to 9 November 2026 in Chicago.
Ad
Bayer Stock: New Analysis - 9 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
